Kevin Joseph Fitzgerald - 12 Feb 2026 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Role
CSO & EVP, Head of Research
Signature
By: Brett Budzinski, Attorney-in-Fact For: Kevin Fitzgerald
Issuer symbol
ALNY
Transactions as of
12 Feb 2026
Net transactions value
-$1,284,980
Form type
4
Filing time
17 Feb 2026, 19:26:59 UTC
Previous filing
14 Jan 2026
Next filing
25 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Fitzgerald Kevin Joseph CSO & EVP, Head of Research 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE By: Brett Budzinski, Attorney-in-Fact For: Kevin Fitzgerald 17 Feb 2026 0001886431

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALNY Common Stock Award $0 +4,000 +19% $0.000000 25,264 12 Feb 2026 Direct F1
transaction ALNY Common Stock Sale $607,448 -1,959 -7.8% $310.08 23,305 13 Feb 2026 Direct F2, F3
transaction ALNY Common Stock Sale $677,532 -2,041 -8.8% $331.96 21,264 17 Feb 2026 Direct F4, F5
holding ALNY Common Stock 537 12 Feb 2026 by Managed Account F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 On February 27, 2023, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of forty (40) percent of the shares subject to the PSU based on the issuer publicly reporting the achievement of non-GAAP operating income for fiscal year 2025 on February 12, 2026, as determined by the People, Culture and Compensation Committee of the Issuer Board of Directors.
F2 Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations.
F3 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $302.55 to $314.60. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4 This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025.
F5 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $329.10 to $334.51. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6 Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.